Trial Information

Summary: Hypertension Study CSAH100A2302

Novartis Pharmaceuticals is conducting this clinical research trial is to determine if the drug combination of aliskiren (Tekturna®), Amlodipine (Norvasc®)and hydrochlorothiazide (HCT) are safe and will effectively lower blood pressure in patients with moderate to severe high blood pressure.

Each drug used alone and the combination of aliskiren/hydrochlorothiazide are approved by the US Food and Drug Administration (FDA) and are available for sale in the U.S.

The combination of aliskiren, hydrochlorothiazide and amlodipine is considered investigational. The word investigational means that this combination is still being tested and is not approved by the FDA and is NOT available for sale in the U.S.

Participants will be required to visit the study center between 9 to 12 times over a duration of 8 weeks.
www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: November 21, 2008 at 2:56:47 PM